磷酸二酯酶-9抑制在实验性心力衰竭中的血流动力学、激素和肾脏作用
本研究首次在正常绵羊和起搏诱导的心力衰竭绵羊中评估磷酸二酯酶-9抑制(PDE9-I)的综合效应。每只动物接受递增静脉推注PDE9-I(30、100、300 mg PF-04749982,间隔1小时)。结果显示PDE9-I剂量依赖性地增加血浆cGMP并降低循环心房利钠肽,同时改善血流动力学和肾脏功能,提示PDE9抑制可能是心力衰竭的新治疗途径。
要点
- PDE9-I剂量依赖性升高血浆cGMP并降低心房利钠肽,提高cGMP/NP比值。
- PDE9-I降低动脉压、心房压和外周阻力,高剂量短暂增加心输出量。
- 心力衰竭模型中PDE9-I增加尿量、钠排泄和肌酐清除率。
核心结论
- PDE9-I改善利钠肽功效,并在实验性心力衰竭中产生有益的血流动力学和肾脏效应。
- 结果支持PDE9在心力衰竭病理生理中发挥作用,其抑制可能构成新的治疗策略。
研究设计与样本
- 研究纳入8只正常绵羊和8只起搏诱导的心力衰竭绵羊。
- 每只动物接受递增静脉推注PDE9-I(30、100、300 mg PF-04749982,间隔1小时)。
主要发现
- 正常绵羊中PDE9-I剂量依赖性增加血浆cGMP(p < 0.05),同时降低循环心房利钠肽(p < 0.01)。
- 心力衰竭中类似趋势使cGMP/NP比值在两种状态下显著升高(分别p < 0.001和p < 0.05)。
- PDE9-I使动脉压(心衰:p < 0.001)、心房压(正常:p < 0.001;心衰:p < 0.001)和外周阻力(心衰:p < 0.001)进行性下降,高剂量短暂增加心输出量(正常:p < 0.05;心衰:p < 0.001)。
- 高剂量后急性增加肾素活性(正常:p < 0.001;心衰:p < 0.05)、血管加压素(正常:p < 0.001;心衰:p < 0.01)和环磷酸腺苷(心衰:p < 0.001)。
- PDE9-I剂量依赖性增加两种状态的尿cGMP(均p < 0.001);心衰中伴随尿量(p < 0.01)、钠排泄(p < 0.01)和肌酐清除率(p < 0.001)增加。
关键数值与推荐
- PDE9-I给药方案:30、100、300 mg PF-04749982静脉推注,间隔1小时。
临床怎么用
- PDE9-I可能通过增强利钠肽信号改善心力衰竭的血流动力学和肾脏功能,但需进一步临床研究验证。
局限性
- 研究为动物实验(绵羊模型),样本量小(正常8只,心衰8只),结果不能直接外推至人类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phosphodiesterase-9 (PDE9) reduces natriuretic peptide (NP) signaling and may be involved in the pathophysiology of heart failure (HF). OBJECTIVES: This study investigated for the first time the integrated hemodynamic, endocrine, and renal effects of phosphodiesterase-9 inhibition (PDE9-I). METHODS: A total of 8 normal sheep and 8 sheep with pacing-induced HF received incremental intravenous boluses of PDE9-I (30, 100, and 300 mg PF-04749982 at 1-h intervals). RESULTS: PDE9-I dose-dependently increased plasma cyclic guanosine monophosphate (cGMP) in normal sheep (p < 0.05) while concurrently reducing circulating atrial natriuretic peptide levels (p < 0.01). Similar trends were evident in HF, resulting in significant elevations in the cGMP/NP ratio in both states (p < 0.001 and p < 0.05, respectively). PDE9-I also produced progressive falls in arterial pressure (HF: p < 0.001), atrial pressure (Normal: p < 0.001; HF: p < 0.001), and peripheral resistance (HF: p < 0.001), and transiently increased cardiac output at the top dose (Normal: p < 0.05; HF: p < 0.001). Inhibition of PDE9 had a negligible effect on circulating hormones at the lower doses, but post-high dose, acutely increased renin activity (Normal: p < 0.001; HF: p < 0.05), vasopressin (Normal: p < 0.001; HF: p < 0.01), and cyclic adenosine monophosphate (HF: p < 0.001). Plasma aldosterone increased briefly after high-dose PDE9-I in normal sheep, and fell following the top dose in HF. PDE9-I dose-dependently increased urinary cGMP in both states (both p < 0.001). In HF, this was associated with increases in urine volume (p < 0.01), sodium excretion (p < 0.01), and creatinine clearance (p < 0.001). CONCLUSIONS: PDE9-I improves NP efficacy in conjunction with beneficial hemodynamic and renal effects in experimental HF. These results support a role for PDE9 in HF pathophysiology and suggest its inhibition may constitute a novel therapeutic approach to this disease.
引用
- Scott NJA, Rademaker MT, Charles CJ, et al. Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure. J Am Coll Cardiol. 2019. PMID: 31416533. doi:10.1016/j.jacc.2019.05.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。